Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.

Saved in:
Bibliographic Details
Title: Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.
Authors: Thompson-Peach CAL; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Thomas D; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Dottore M; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Lim K; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Stomski F; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Panagopoulos RA; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Foßelteder J; Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Reinisch A; Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Chandrakanthan V; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Jenkner S; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Bland L; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Paton S; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Gronthos S; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Hercus TR; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Wardill HR; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Kan WL; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Kamel MM; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Moretti PA; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Pitson SM; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Burbury K; Department of Clinical Haematology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia., Ross DM; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia.; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia.; Department of Haematology, Flinders University and Medical Centre, Adelaide, Australia., Nair PC; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, and School of Medicine, College of Health, Adelaide University, Adelaide, Australia.; Department of Haematology, Flinders University and Medical Centre, Adelaide, Australia.; Discipline of Clinical Pharmacology, Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, Australia., Lopez AF; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia., Tvorogov D; Division of Human Immunology SA Pathology, and Centre for Cancer Biology, Adelaide University, Adelaide, Australia.
Source: Blood [Blood] 2026 Apr 02; Vol. 147 (14), pp. 1611-1623.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2024027897